Thomas Taapken

Thomas Taapken is an Independent Board Member at Memo Therapeutics. Prior to this, they were with InflaRx, Imcyse SA, consultant and board member, Immunic AG, Medigene AG, SciBase, and Epigenomics AG.

Thomas has over 15 years of experience in the biotech and pharmaceutical industries. Thomas started their career as a CFO and has since held various management positions. In 2008, they became the CEO and CFO of Epigenomics AG where they successfully restructured the company and raised over EUR 40 million in private and public offerings. In 2016, the company received US FDA PMA approval for Epi proColon, the first and so far only FDA approved blood test for colorectal cancer screening.

Under Thomas's leadership, Medigene AG raised over EUR 50 million in two private placements in 2017 and 2018. Thomas also served as a member of the supervisory board of Immunic AG which became a NASDAQ listed company (IMUX) through the reverse merger process in 2019.

Thomas Taapken pursued a Ph.D. in Chemistry at Technische Universität Berlin, followed by a Diploma in Chemistry from The University of Göttingen.